RxDoctor Payments Data

Jose Betancourt, MD

Cardiovascular Disease · Keene, NHNPI 1992748149

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (55.2%), food and beverage and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Boston Scientific at 39.8% of the total. Reporting peaked in 2019 at $7,214 and has fallen 99.8% since, to $13 in 2024.

$8,221in general payments, 2019–2025

Across 58 payments — averaging $141.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Medtronic$2K
  • Biotronik Inc.$1K
  • Baylis Medical Company Inc$352
  • Heartflow, Inc.$252
  • Biosense Webster, Inc.$170
  • plus $283 from 6 others

What the payments were for

  • Travel & lodging$4,53555%
  • Food & beverage$3,25240%
  • Education$4345%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,221 in reported general payments places this provider in the 85th percentile of 112 cardiovascular disease providers in New Hampshire.

See all cardiovascular disease providers in New Hampshire

Medicare billing

Part B allowed, 2024
$48,679
Medicare patients
431
Services billed
597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$73,630
EntrestoSacubitril/Valsartan26$18,521
XareltoRivaroxaban13$7,661
Rosuvastatin Calcium52$2,520
Atorvastatin Calcium111$1,804
Metoprolol Succinate168$1,593
Ranolazine ErRanolazine15$1,313
PaceroneAmiodarone Hcl24$854
Losartan Potassium102$835
ClopidogrelClopidogrel Bisulfate27$831
Diltiazem 24hr Er (Cd)Diltiazem Hcl17$444
Nebivolol Hcl11$440
Carvedilol84$404
Spironolactone33$272
Nitroglycerin18$255

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Keene

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →